长期的安全性和减少的药丸负担的tenapanor治疗:一个第3阶段的开放标签研究在血液透析患者高酸血症
Fumihiko Koiwa1, Yu Sato2, Meiko Ohara2
1Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-Ku, Yokohama, 227-8501, Japan. koiwa-f@med.showa-u.ac.jp.
Scientific reports
|November 5, 2023
概括
一种新型药物Tenapanor通过降低酸盐吸收,有效地减少了血液透析患者的每日药片负担. 这项研究证明了其在控制血清水平方面的长期安全性和耐受性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 酸盐结合剂 (PBs) 往往给患者带来很大的药物负担.
- 帕诺尔通过抑制肠道酸盐吸收提供了一种新的治疗方法.
- 对患有慢性脏病的患者来说,管理高酸血症至关重要.
研究的目的:
- 评估特纳帕诺尔在血液透析患者的长期安全性和耐受性.
- 评估特纳帕诺尔在减少酸盐结合剂的整体每日药片负担方面的有效性.
- 在延长的tenapanor治疗期间监测血清水平.
主要方法:
- 一个多中心,开放标签,单臂,第三阶段研究.
- 给血液透析患者,血清含量升高的Tenapanor (5-30毫克每天两次) 进行治疗.
- 患者可以从现有的酸盐结合剂转换为tenapanor.
主要成果:
- 77.5%的患者实现了每日药片数量减少≥30%.
- 腹是最常见的不良事件 (63.7%),大多是轻微的.
- 血清含量在目标范围 (3.5-6.0 mg/dl) 内保持稳定.
结论:
- 帕诺在血液透析患者中证明了长期的安全性和耐受性.
- 帕诺尔有效地减少或消除了对传统酸盐结合剂的需求.
- 这种新型药物为管理高酸血症和改善患者坚持治疗提供了一个有希望的策略.
相关概念视频
Chronic Kidney Disease III: Interprofessional Care
13
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
13
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
163
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
163
Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
177
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
177
Hemodialysis III: Nursing Management
25
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
25
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438


